Out Of The Ashes: Roche’s Dalcetrapib Data Suggest Still Hope For CETP Inhibitor Class

Experts see various reasons why Roche’s HDL-raising drug may have failed to demonstrate benefit in the dal-OUTCOMES study, including insufficient potency resulting from only partial CETP inhibition. Final word on the class’ fate likely will not be written until outcomes studies by Merck and Lilly report out in several years.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet